Corona Remedies (NSE:CORONA) EBIT: ₹1,751 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:CORONA Corona Remedies Ltd NSE:CORONA
18 GF Score
Price ₹2,098.80
! 3 Warning Signs
View Full Analysis

What is Corona Remedies EBIT?

Corona Remedies NSE:CORONA +0.37% 18 EBIT is ₹1,751 Mil as of Mar. 2026. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

Corona Remedies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹561 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,751 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Corona Remedies's annualized ROC % for the quarter that ended in Mar. 2026 was 16.53%. Corona Remedies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 39.49%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Corona Remedies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.35%.

Corona Remedies  (NSE:CORONA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Corona Remedies's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=2069.2 * ( 1 - 17.19% )/( (0 + 10365.2)/ 1 )
=1713.50452/10365.2
=16.53 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12051.4 - 1814.8 - ( 18.3 - max(0, 3611.7 - 3483.1+18.3))
=10365.2

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Corona Remedies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2244.8/( ( (0 + max(0, 0)) + (4378.3 + max(1306.5, 0)) )/ 1 )
=2244.8/( ( 0 + 5684.8 )/ 1 )
=2244.8/5684.8
=39.49 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1455.5 + 1250 + 753) - (1814.8 + 0 + 337.2)
=1306.5

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Corona Remedies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1750.73/129992.993
=1.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corona Remedies EBIT Related Terms

Corona Remedies EBIT Historical Data

* Premium members only.

The historical data trend for Corona Remedies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corona Remedies EBIT Chart

Corona Remedies Annual Data
Trend Mar23 Mar24 Mar25 Mar26
EBIT
1,132.72 1,299.76 2,065.70 2,449.90

Corona Remedies Quarterly Data
Mar23 Mar24 Dec24 Mar25 Jun25 Dec25 Mar26
EBIT Get a 7-Day Free Trial 606.70 458.10 620.83 568.70 561.20

NSE:CORONA vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Corona Remedies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corona Remedies EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Corona Remedies's EV-to-EBIT falls into.


NSE:CORONA
18GF Score
Corona Remedies Ltd NSE:CORONA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corona Remedies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,751 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹1,751 Mil mean?
Corona Remedies (NSE:CORONA) has a EBIT of ₹1,751 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Corona Remedies.
Is Corona Remedies' EBIT too high?
Corona Remedies' current EBIT is ₹1,751 Mil. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' EBIT compare to LLY and JNJ?
Corona Remedies' EBIT of ₹1,751 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Corona Remedies. Corona Remedies's current EBIT is ₹1,751 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current EBIT of ₹1,751 Mil. The current EBIT is ₹1,751 Mil. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current EBIT is ₹1,751 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corona Remedies Business Description

Other Exchanges 544644:India
Address S. G. Highway, CORONA House, C - Mondeal Business Park, Near Gurudwara, Thaltej, Ahmedabad, GJ, IND, 380 059
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score

Get the complete analysis for NSE:CORONA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,098.80
Price